CTOs on the Move

Metabolic Solutions Development

www.msdrx.com

 
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.msdrx.com
  • 161 E. Michigan Ave. 4th Floor
    Kalamazoo, MI USA 49007
  • Phone: 269.343.6732

Executives

Name Title Contact Details

Funding

Metabolic Solutions Development raised $16.1M on 09/25/2015

Similar Companies

Ferndale Laboratories

Ferndale Laboratories, Inc. is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pioneer Surgical Technology

Pioneer Surgical Technology is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orascoptic

Orascoptic offers award-winning, custom-fit dental and surgical loupes and headlights for loupes with a 45-day trial period.

RxNT

RxNT is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.